NCT07030062 Echocardiography Guided TAVR (Echo TAVR)
| NCT ID | NCT07030062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pan Xiangbin |
| Condition | Transcatheter Aortic Valve Replacemen |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-18 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-02-18 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.
Eligibility Criteria
Inclusion Criteria: 1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2); 2. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures; 3. chronic kidney disease and refuse to receive contrast agents or radiation exposure. Exclusion Criteria: Required hybrid procedures or concomitant interventions on other cardiac malformations; Deemed inoperable due to extremely high surgical risk or severe comorbidities; Had untreated clinically significant coronary vascular disease amenable to revascularization; Previously undergone aortic valve replacement.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07030062 clinical trial?
This trial is open to participants of all sexes, studying Transcatheter Aortic Valve Replacemen. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07030062 currently recruiting?
Yes, NCT07030062 is actively recruiting participants. Contact the research team at panxiangbin@fuwaihospital.org for enrollment information.
Where is the NCT07030062 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07030062 clinical trial?
NCT07030062 is sponsored by Pan Xiangbin. The trial plans to enroll 20 participants.